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hemolytic diseases and the red blood cell storage
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Intravascular red cell hemolysis impairs NO-redox homeos-
tasis, producing endothelial dysfunction, platelet activation
and vasculopathy. A central mechanism is that cell-free
plasma hemoglobin reacts with the vasodilator nitric oxide
(NO) in a 1:1 stoichiometric reaction that occurs at high
rate of 6-8x107 mol/L/s. This consumption of NO by cell
free plasma hemoglobin has been shown to cause changes
in vascular function in subjects with sickle cell anaemia
who had plasma heme concentrations as low as 6 µM.
Approximately half of the observed “hemolysis” in stored
blood is also encapsulated in microparticles, and, in theory,
based on their small molecular size, microparticles may
also exhibit accelerated NO scavenging rates compared
with intact erythrocytes. The effect of microparticles on
NO scavenging could be especially important, particularly
in the microvasculature where their clearance may not be
reflected by systemic clearance rates. Red blood cell storage
under standard blood banking conditions results in reduced
integrity of the erythrocyte membrane, with formation of
exocytic microvesicles or “microparticles” and hemolysis,
which we hypothesized could impair vascular function and
contribute to the putative “storage lesion” of banked blood.
We now find that storage of human red blood cells under
standard blood banking conditions results in the accumula-
tion of cell free and microparticle-encapsulated hemoglobin
which, despite 39 days of storage, remains in the reduced
ferrous oxyhemoglobin redox state and stoichiometrically
reacts with and scavenges the vasodilator NO. Using
stopped-flow spectroscopy and laser triggered NO release
from a caged NO compound we found that both free
hemoglobin and microparticles react with NO about 1000
times faster than with intact erythrocytes. In complemen-
tary in vivo studies we show that hemoglobin, even at con-
centrations below 10 µM (in heme), produces potent
vasoconstriction when infused into the rat circulation,
while controlled infusions of methemoglobin and cyano-
methemoglobin, which do not consume NO, have substan-
tially reduced vasoconstrictor effects. Infusion of the
plasma from stored human red cell units into the rat circu-
lation produces significant vasoconstriction related to the
magnitude of storage related hemolysis. Finally, we
explored new therapies that have the potential to bypass
NO scavenging via direct pharmacological activation of
soluble guanylyl cyclase (sGC). These sGC activators or sti-
mulators show promise in the reversal of free-hemoglobin
mediated vasoconstriction. The results of these studies sug-
gest new mechanisms for endothelial injury and impaired
vascular function associated with the most fundamental of
red blood cell storage lesions, hemolysis, as well as suggest
a new approach to therapeutic restoration of cGMP levels
in the setting of NO scavenging reactions.
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